1. Cook A, Giunti P. Friedreich's ataxia: clinical features, pathogenesis and management. British medical bulletin. 2017;124(1):19-30.
2. Zhang S, Napierala M, Napierala JS. Therapeutic Prospects for Friedreich's Ataxia. Trends in pharmacological sciences. 2019;40(4):229-33
3. Tai G, Corben LA, Yiu EM, Milne SC, Delatycki MB. Progress in the treatment of Friedreich ataxia. Neurologia i neurochirurgia polska. 2018;52(2):129-39.
4. Gonzalez-Cabo P, Palau F. Mitochondrial pathophysiology in Friedreich's ataxia. Journal of neurochemistry. 2013;126 Suppl 1:53-64.
5. Alfedi G, Luffarelli R, Condò I, Pedini G, Mannucci L, Massaro DS, et al. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia. movement disorders. 2019;34(3):323-34.
6. Schulz JB, Boesch S, Bürk K, Dürr A, Giunti P, Mariotti C, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nature Reviews Neurology. 2009;5:222.
7. Strawser C, Schadt K, Hauser L, McCormick A, Wells M, Larkindale J, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert review of neurotherapeutics. 2017;17(9):895-907.
8. Rezaeizadeh H, Alizadeh M, Naseri M, Ardakani MR Shams. The Traditional Iranian Medicine Point of View on Health and disease. Iranian Journal of Public Health. 2009;38(1):169-72.
9. Shirbeigi L, Zarei A, Naghizadeh A, Vaghasloo M.A., The concept of temperaments in traditional Persian medicine. Traditional & Integrative Medicine. 2017:143-56.